Novel therapeutic strategies leveraging T_H9 cell anticancer functions

T_H9 cells, a distinct subset of CD4⁺ T helper cells characterized by IL-9 production, have emerged as key players in cancer immunology. Initially recognized for their potent antitumor activity upon adoptive cell transfer against melanoma, recent studies have revealed a more complex and context-dependent role, where T_H9 cells support antitumor immunity through multiple mechanisms. This review explores the contribution of T_H9 cells in cancer, emphasizing their importance in response to tumor microenvironmental cues such as hypoxia, metabolic changes, and interactions with stromal and myeloid cells. We also highlight novel therapeutic strategies leveraging T_H9 cell anticancer functions, including adoptive transfer, cytokine engineering, and metabolic reprogramming, as well as their potential integration into existing immunotherapy strategies, including immune checkpoint inhibitors and CAR-T cell therapies. Understanding the mechanisms responsible for driving T_H9 cell-mediated immunity will be instrumental to confirm their relevance in next-generation immunotherapeutic strategies.